Advanced search
1 file | 1.04 MB Add to list

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Author
Organization
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option in both adult and pediatric patients with malignant and non-malignant hematological diseases. Chimerism analysis, which determines the donor or recipient origin of hematopoietic cells in HSCT recipients, is an essential aspect of post-HSCT follow-up.Objectives: To review the current literature and develop Belgian consensus guidelines for the use of chimerism analysis in the standard of care after allogeneic HSCT.Methods: Non-systematic review of the literature in consultancy with the members of the BHS transplantation committee.Results: Clinical application with regards to prediction of graft failure or relapse as well as cell source are reviewed. A consensus guideline on the use of chimerism analysis after HSCT is presented.Conclusion: Monitoring of the dynamics or kinetics of a patient's chimerism status by serial analysis at fixed time points, as well as on suspicion of relapse or graft failure, is needed to monitor engraftment levels, as well as disease control and possible relapse.
Keywords
ACUTE MYELOID-LEUKEMIA, MINIMAL RESIDUAL DISEASE, FULL DONOR CHIMERISM, HEMATOPOIETIC CHIMERISM, PERIPHERAL-BLOOD, REAL-TIME, QUANTITATIVE-ANALYSIS, REDUCED-INTENSITY, PEDIATRIC-PATIENTS, MIXED, CHIMERISM, Allogeneic stem cell transplantation, chimerism, minimal residual, disease, graft failure

Downloads

  • Use of chimerism analysis after allogeneic stem cell transplantation Belgian guidelines and review of the current literature.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.04 MB

Citation

Please use this url to cite or link to this publication:

MLA
Delie, Anke, et al. “Use of Chimerism Analysis after Allogeneic Stem Cell Transplantation: Belgian Guidelines and Review of the Current Literature.” ACTA CLINICA BELGICA, Taylor & Francis Ltd, 2020, doi:10.1080/17843286.2020.1754635.
APA
Delie, A., Verlinden, A., Beel, K., Deeren, D., Mazure, D., Baron, F., … Kerre, T. (2020). Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. ACTA CLINICA BELGICA. https://doi.org/10.1080/17843286.2020.1754635
Chicago author-date
Delie, Anke, Anke Verlinden, Karolien Beel, Dries Deeren, Dominiek Mazure, Frederic Baron, Dimitri Breems, et al. 2020. “Use of Chimerism Analysis after Allogeneic Stem Cell Transplantation: Belgian Guidelines and Review of the Current Literature.” ACTA CLINICA BELGICA. https://doi.org/10.1080/17843286.2020.1754635.
Chicago author-date (all authors)
Delie, Anke, Anke Verlinden, Karolien Beel, Dries Deeren, Dominiek Mazure, Frederic Baron, Dimitri Breems, Ann De Becker, Carlos Graux, Philippe Lewalle, Johan Maertens, Xavier Poire, Helene Schoemans, Dominik Selleslag, Florence Van Obbergh, and Tessa Kerre. 2020. “Use of Chimerism Analysis after Allogeneic Stem Cell Transplantation: Belgian Guidelines and Review of the Current Literature.” ACTA CLINICA BELGICA. doi:10.1080/17843286.2020.1754635.
Vancouver
1.
Delie A, Verlinden A, Beel K, Deeren D, Mazure D, Baron F, et al. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. ACTA CLINICA BELGICA. 2020;
IEEE
[1]
A. Delie et al., “Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature,” ACTA CLINICA BELGICA, 2020.
@article{8668511,
  abstract     = {Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option in both adult and pediatric patients with malignant and non-malignant hematological diseases. Chimerism analysis, which determines the donor or recipient origin of hematopoietic cells in HSCT recipients, is an essential aspect of post-HSCT follow-up.Objectives: To review the current literature and develop Belgian consensus guidelines for the use of chimerism analysis in the standard of care after allogeneic HSCT.Methods: Non-systematic review of the literature in consultancy with the members of the BHS transplantation committee.Results: Clinical application with regards to prediction of graft failure or relapse as well as cell source are reviewed. A consensus guideline on the use of chimerism analysis after HSCT is presented.Conclusion: Monitoring of the dynamics or kinetics of a patient's chimerism status by serial analysis at fixed time points, as well as on suspicion of relapse or graft failure, is needed to monitor engraftment levels, as well as disease control and possible relapse.},
  author       = {Delie, Anke and Verlinden, Anke and Beel, Karolien and Deeren, Dries and Mazure, Dominiek and Baron, Frederic and Breems, Dimitri and De Becker, Ann and Graux, Carlos and Lewalle, Philippe and Maertens, Johan and Poire, Xavier and Schoemans, Helene and Selleslag, Dominik and Van Obbergh, Florence and Kerre, Tessa},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {ACUTE MYELOID-LEUKEMIA,MINIMAL RESIDUAL DISEASE,FULL DONOR CHIMERISM,HEMATOPOIETIC CHIMERISM,PERIPHERAL-BLOOD,REAL-TIME,QUANTITATIVE-ANALYSIS,REDUCED-INTENSITY,PEDIATRIC-PATIENTS,MIXED,CHIMERISM,Allogeneic stem cell transplantation,chimerism,minimal residual,disease,graft failure},
  language     = {eng},
  pages        = {9},
  publisher    = {Taylor & Francis Ltd},
  title        = {Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature},
  url          = {http://dx.doi.org/10.1080/17843286.2020.1754635},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: